Movement Alert｜INNOVENT BIO Declines 3.1% in Regular Trading, Profit-Taking Follows Record High After Earnings Beat

Market Focus11:10

On August 27, INNOVENT BIO fell 3.1% in regular trading, trading at HK$106.2/share, with turnover of HK$743 million. The stock retreated after surging 9.69% the prior session to an all-time high of HK$112.2, driven by better-than-expected interim results.

The pullback reflects concentrated profit-taking following the sharp post-earnings rally. On August 25, the company reported H1 total revenue of RMB 8.618 billion, up 44.8% year-over-year, with product revenue of RMB 8.201 billion representing 56.7% growth. IFRS net profit reached RMB 1.253 billion, a 50.2% increase that already surpassed full-year 2025 levels. Despite the strong fundamentals, the rapid price appreciation triggered selling pressure, compounded by broader biotech sector weakness — CanSinoBIO declined 6.78%, Everest Medicines fell 3.17%, and BeiGene dropped 1.49% on the same session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184652086?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 11:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184652086","market":"us","top_or_hot":-1,"title":"Movement Alert｜INNOVENT BIO Declines 3.1% in Regular Trading, Profit-Taking Follows Record High After Earnings Beat","media":"Market Focus","content":"<p><p>On August 27, INNOVENT BIO fell 3.1% in regular trading, trading at HK$106.2/share, with turnover of HK$743 million. The stock retreated after surging 9.69% the prior session to an all-time high of HK$112.2, driven by better-than-expected interim results.</p><p>The pullback reflects concentrated profit-taking following the sharp post-earnings rally. On August 25, the company reported H1 total revenue of RMB 8.618 billion, up 44.8% year-over-year, with product revenue of RMB 8.201 billion representing 56.7% growth. IFRS net profit reached RMB 1.253 billion, a 50.2% increase that already surpassed full-year 2025 levels. Despite the strong fundamentals, the rapid price appreciation triggered selling pressure, compounded by broader biotech sector weakness — CanSinoBIO declined 6.78%, Everest Medicines fell 3.17%, and BeiGene dropped 1.49% on the same session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INNOVENT BIO Declines 3.1% in Regular Trading, Profit-Taking Follows Record High After Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INNOVENT BIO Declines 3.1% in Regular Trading, Profit-Taking Follows Record High After Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-27 11:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 27, INNOVENT BIO fell 3.1% in regular trading, trading at HK$106.2/share, with turnover of HK$743 million. The stock retreated after surging 9.69% the prior session to an all-time high of HK$112.2, driven by better-than-expected interim results.</p><p>The pullback reflects concentrated profit-taking following the sharp post-earnings rally. On August 25, the company reported H1 total revenue of RMB 8.618 billion, up 44.8% year-over-year, with product revenue of RMB 8.201 billion representing 56.7% growth. IFRS net profit reached RMB 1.253 billion, a 50.2% increase that already surpassed full-year 2025 levels. Despite the strong fundamentals, the rapid price appreciation triggered selling pressure, compounded by broader biotech sector weakness — CanSinoBIO declined 6.78%, Everest Medicines fell 3.17%, and BeiGene dropped 1.49% on the same session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1184652086","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184652086","pubTimestamp":1787800223,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 27, INNOVENT BIO fell 3.1% in regular trading, trading at HK$106.2/share, with turnover of HK$743 million. The stock retreated after surging 9.69% the prior session to an all-time high of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"走势警报|信达生物常规交易下跌 3.1%，盈利超出预期后获利回吐创历史新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On August 27, INNOVENT BIO fell 3.1% in regular trading, trading at HK$106.2/share, with turnover of HK$743 million. The stock retreated after surging 9.69% the prior session to an all-time high of HK$112.2, driven by better-than-expected interim results.The pullback reflects concentrated profit-taking following the sharp post-earnings rally. On August 25, the company reported H1 total revenue of RMB 8.618 billion, up 44.8% year-over-year, with product revenue of RMB 8.201 billion representing 56.7% growth. IFRS net profit reached RMB 1.253 billion, a 50.2% increase that already surpassed full-year 2025 levels. Despite the strong fundamentals, the rapid price appreciation triggered selling pressure, compounded by broader biotech sector weakness — CanSinoBIO declined 6.78%, Everest Medicines fell 3.17%, and BeiGene dropped 1.49% on the same session.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184652086","isCrawlerRequest":true}